Selected video interviews.
National oncology media appearances translating fast-moving myeloma science for clinicians and patients.
A Personal Mission: On Myeloma's Transformation
How a family diagnosis shaped a career, and how far treatment has come.
Real-World Roles of Cilta-Cel and Ide-Cel in R/R Myeloma
How earlier-line CAR T-cell therapy approvals are shifting the paradigm.
Unmet Needs After Early CAR T-cell Therapy in R/R Myeloma
What still needs solving after earlier-line cellular therapy.
Unmet Needs Following Early-Line CAR T-cell Therapy
A cell & gene therapy lens on sequencing after early CAR T-cell therapy.
Integrating MajesTEC-9 Data Into Treatment Decisions
How new data may influence therapy selection in R/R myeloma.
Optimizing Dosing Strategies for Bispecific Antibodies
Evolving dosing approaches in relapsed/refractory disease.
The Evolving Role of FcRH5-Targeted Therapy
The potential of cevostamab and FcRH5-directed treatment.
Cevostamab May Fill a Gap in the Armamentarium
Where a novel bispecific could fit among today's options.
Therapy Is Only as Good as Its Access
Why equitable access is central to real-world outcomes.
Best of ASCO® 2026, Pittsburgh
Presenting the most important practice-changing advances in multiple myeloma. "What makes these meetings valuable is not just discussing new developments, it is examining how we translate that evidence into better treatment selection, thoughtful sequencing, and meaningful outcomes for our patients."
On the podium
Recent invited presentations across national myeloma and cellular therapy meetings.
On panels and main stages
Panel discussions and plenary sessions at national meetings.
